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Bacterial-directed enzyme prodrug therapy (BDEPT) is an emerging form of treatment for 
cancer. It is a biphasic variant of gene therapy in which a bacterium, armed with an enzyme 
that can convert an inert prodrug into a cytotoxic compound, induces tumour cell death 
following tumour-specific prodrug activation. BDEPT combines the innate ability of bacteria 
to selectively proliferate in tumours, with the capacity of prodrugs to undergo contained, 
compartmentalised conversion into active metabolites in vivo. Although BDEPT has 
undergone clinical testing, it has received limited clinical exposure, and has yet to achieve 
regulatory approval. In this article, we review BDEPT from the system designer’s 
perspective, and provide detailed commentary on how the designer should strategize its 
development de novo. We report on contemporary advancements in this field which aim to 
enhance BDEPT in terms of safety and efficacy. Finally, we discuss clinical and regulatory 
barriers facing BDEPT, and propose promising approaches through which these hurdles may 
best be tackled.  
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Off-target toxicity is a key limitation in cancer chemotherapy, where the concentration of 
drug usually required for efficacy is too toxic to the patient, inducing unacceptable side 
effects and preventing tumour clearance. To overcome this, several substitute strategies have 
been developed over the years which aim to localise treatment to the site of the tumour, thus 
sparing healthy tissue. One such strategy involves gene therapy, whereby drug delivery 
vehicles are engineered to carry nucleic acids to tumour cells, encouraging the production of 
anticancer biomolecules. Early gene therapies relied heavily on viruses to serve as gene 
carriers [1, 2], but the scope of what can be regarded as a carrier has since expanded beyond 
viral vehicles to include bacteria. The use of bacteria in treating cancer, however, predates 
discussion of gene therapy by decades. It was initially pioneered over a century ago by 
William Coley, after he observed that some cancers of hospitalised patients regressed 
following accidental Streptococcus pyogenes infections, and by Friedrich Fehleisen, who had 
begun treating oncology patients with the same microbe during the same period [3, 4]. These 
accounts prompted further research on bacteria in the treatment of cancer, although, as this 
method was not at the time curative, it was gradually abandoned.   
In the mid-20
th
 century, it became apparent that bacteria can preferentially accumulate within 
tumour tissue. For example, the systemic injection of Clostridium tetani spores into mice led 
to the exclusive localisation of their vegetative form in murine tumours [5]. It has since 
emerged that some bacteria possess inherent anticancer attributes, without the requirement for 
‘arming’ them with heterologous genes. Intracellular replication of invasive bacteria (e.g. 
salmonellae) within cancer cells can induce apoptosis, while certain species-specific toxins 
have been identified, such as with propionibacteria, which can induce apoptosis in colorectal 
carcinoma cells with fatty acids that are naturally produced by this genus [6]. Similarly, 
unmodified Lactococcus lactis is cytotoxic to cancer cells and impedes proliferation in 
several cancer cell lines [7]. With the birth of molecular biology in the late 20
th
 century, 
interest in bacteria as anticancer agents has reignited in earnest. The field is continually 
evolving, and different preclinical approaches exist which investigate bacteria as tumour-
selective entities [8]. Rather than simply viewing bacteria as unmodifiable agents for treating 
cancer, as they were recognised during Coley’s and Fehleisen’s time, we have since re-
considered their flexibility and have postulated their usability in conjunction with other, more 
















One such treatment type is gene-directed enzyme prodrug therapy (GDEPT), which uses gene 
therapy techniques to enzymatically convert inactive prodrugs to their active drug 
counterparts [9]. GDEPT is a growing discipline that was initially conceived to invoke 
differential expression of enzymes in tumour tissue compared with healthy tissue for 
medicinal purposes. It essentially encapsulates the tumour-specific expression of a gene, 
coding for a prodrug-converting enzyme, which logistically leads to the tumour-specific 
activation of an administered prodrug. Different manifestations of GDEPT exist, 
characterised by gene delivery that is assisted by carriers predisposed to tumour entry, such 
as viral-directed enzyme prodrug therapy (VDEPT) [10]. Gene expression can be controlled 
by ensuring that transcription occurs via a promoter operating only within tumour cells [11]. 
This promoter can be either a constituent of the carrier’s genome or part of the tumour cell’s 
default machinery.  
The union of bacteria and GDEPT yields bacterial-directed enzyme prodrug therapy 
(BDEPT), also referred to as bacterial prodrug therapy, which constitutes a two-step 
procedure for treating cancer using bacteria as in situ sources of prodrug-converting enzymes 
[12]. In the first phase of treatment, bacteria, that have been armed with a gene coding for an 
enzyme that can convert an inert prodrug into a cytotoxic active pharmaceutical ingredient 
(API), are administered to the patient. The bacteria travel to the tumour site, preferentially 
colonise it, and then begin to proliferate. Once intratumoural bacterial numbers are adequate, 
and enzyme production amplified, the second step is initiated by administering the prodrug. 
Following administration, the prodrug spreads systemically throughout the body, but is 
primarily activated in the tumour by the locally-produced enzyme. The API diffuses then 
throughout the malignancy, relieving healthy tissue of any damage. As the active drug is 
generated locally inside the tumour, this approach can be thought of as in situ chemotherapy 
(Figure 1).  
The administration of a prodrug has enormous benefits over administering a drug pre-
formulated as an API. Ideally, prodrugs are synthesised with certain molecular features that 
conceal an underlying pharmacodynamic mechanism of action [13]. These features often 
bestow upon the drug improved pharmacokinetic qualities, augmenting its bioavailability in 
vivo. Described as a “chemistry-enabled drug delivery tool”, prodrugs are metabolised to 
their active form, following administration, by either endogenous or exogenous enzymes 
[14]. As the core therapeutic objective which GDEPT seeks to accomplish revolves around 
















enzymes is inadvisable. This is because the prodrug is liable to encounter the enzyme en 
route to the tumour, resulting in extra-tumoural toxicity [15]. Contrastingly, a prodrug which 
is activated by an exogenous enzyme gives the clinician significant control regarding the 
calibration of the patient’s treatment, allowing them to time the site-specific initiation of 
therapy, if the enzyme is guided to the tumour appropriately.  
 
Figure 1. Bacterial-directed enzyme prodrug therapy. The two-step procedure of BDEPT is 
illustrated, wherein bacteria expressing a prodrug-converting enzyme are administered to an 
oncology patient (step 1), followed by systemic administration of a corresponding prodrug 
when the tumour is adequately colonised (step 2). The in situ bacterial-mediated conversion 
of 5-fluorocytosine (a prodrug) to 5-fluorouracil (an API) is illustrated in step 2.  
 
















Bacteria have many characteristics which favour them as tumour-targeting agents over other 
transduction and transfection methodologies. Firstly, they are naturally tumour-selective. A 
diverse panel of bacteria, including Gram-positive, Gram-negative, aerobic, and anaerobic 
strains, has illustrated the selective colonisation of various tumour models by all microbes 
under study [16]. Secondly, bacteria proliferate post-delivery, unlike replication-defective 
viruses, such as adenoviruses, and non-viral carriers [17-19]. Thirdly, the genomic capacity 
of bacteria is far greater than that of viruses, making them more amenable to genetic 
engineering [20]. In fact, a range of therapeutic biomolecules has been used in conjunction 
with harmless or mildly toxic bacteria, ranging from cytokines to antigens [21-24]. Finally, in 
the case of emergency, bacteria can be cleared from the patient by antibacterial agents [25] - 
something which is impossible with other gene therapy carriers.  
The nature of tumour-selective colonisation is dependent on a multitude of factors, many of 
which relate to passive features of malignant tissue. The abnormal, porous vasculature of the 
tumour facilitates penetration of bacteria, in which they lodge and begin to proliferate, 
protected naturally from immune surveillance [26]. Immunity serves to quickly clear extra-
tumoural bacteria from the bloodstream and non-malignant tissue following administration to 
humans [25, 27] and animals [28-30], but it also complicates tumour-specific colonisation of 
the carrier. Threshold administration quantities of microbes to induce colonisation are 
apparent, and it is likely that once a threshold is exceeded, host innate immune defences are 
insufficient to neutralise all microbes before they encounter the malignancy [16, 31]. Indeed, 
while even obligate anaerobic bacteria, such as Bifidobacterium breve UCC2003, have been 
recovered from healthy organs distal to tumours, tumour-to-liver colonisation ratios in the 
region of 10000:1 have been reported for these microbes [32]. Some bacterial genera have 
been shown to exclusively colonise tumour areas characterised by hypoxia or anoxia, while 
others are capable of colonising both necrotic and normoxic tissues [33, 34]. Growth usually 
occurs in multiple groups of colonies inside the tumour [35, 36]. The proliferation of bacteria 
in vivo is contingent on the availability of certain nutrients such as iron [37]. This dependence 
can be exploited by host immune defences by curtailing the availability of such nutrients, to 
counteract the accumulation of bacteria [38]. Not only do tumours protect microbes within it 
from host defences, but tumour tissues hold a wealth of nutrients, such as amino acids, that 
provide vital sustenance for bacteria, especially in the case of auxotrophic mutants [30, 39]. 
There is some evidence suggesting that bacteria are attracted to tumours (or their 
















necrotic cancer cells [40], propelled there by their own motility [41]. It has also been 
purported, contrarily, that motility has a negligible effect on bacterial migration to tumours 
[42]. Colonisation correlates positively with tumour size [43], probably because large, 
advanced tumours contain marked hypoxia, amenable to more extensive colonisation [44]. 
However, some tumours as small as 20 mm
3 
have proven to be colonisable by bacteria [26]. 
The unification of bacterial systems and enzyme-mediated prodrug activation is ideal. 
Commensal bacterial genes typically code for enzymes, and not toxins, and thus are unlikely 
to be lethal to the host [45]. Furthermore, in the event of bacterial leakage from the tumour 
into the bloodstream, iatrogenic effects of the API are minimised, as these microbes will be 
rapidly and systemically eliminated from non-malignant tissue by the immune system. 
Pathogenic bacteria, such as Clostridium difficile, having an innate ability to kill healthy host 
cells through exotoxin production, can kill tumour cells when in proximity [46]. Despite the 
tumour-selective growth of bacteria, the non-specific toxicity of pathogenic microbes does 
not provide a therapeutic index wide enough for safe and effective BDEPT [5]. Modified 
strains with reduced virulence, or inherently non-pathogenic bacteria, present an opportunity 
to circumvent this. For example, Clostridium novyi, heat-treated to abolish one of its lethal 
toxins, brought about tumour regression in mice following administration, probably due to 
the release of oncolytic products from the bacterium [47]. The attenuated strain C. novyi-NT 
has been explored preclinically in combination with other tumour-targeting entities, such as 
liposomally-encapsulated chemotherapies, for its natural facility to enzymatically release the 
contents of liposomes [48]. This strain has also been combined with more conventional forms 
of cancer treatment, including radiation therapy, as a means of specifically targeting hypoxic 
tumour regions, against which radiation is known to be less effective [49]. Currently, C. 
novyi-NT is being clinically studied in patients with cancers that are refractory to standard 
treatment (clinicaltrials.gov identifier: NCT01924689) [50].  
 
Constructing a Successful BDEPT: Design Principles  
Putting aside everything which makes BDEPT promising, it has yet to achieve a place in the 
standard anticancer repertory of the clinic, and it is worth examining why this is so. BDEPT 
is not by any means a “traditional” kind of treatment, and it is unlike any form of anticancer 
therapy currently in clinical use. Non-targeted chemotherapies and monoclonal antibodies, 
















on living delivery vehicles for conveyance to their sites of action. BDEPT designers, having 
no blueprint of what a truly effective BDEPT really looks like yet, are compelled to feel their 
way as they search for successful therapies of this kind. It is therefore imperative to have a 
solid understanding of all design variables and how best to tailor them for optimisation of 



















Figure 2. BDEPT Design Process Flow. An illustration of the order in which the de novo design of BDEPT should be approached. The process 
is divided into five distinct design principles. Curved arrows pointing from one design principle to another indicate a relationship in which an 

















Design Principle I: Small-Molecule Pharmacokinetics  
The most pertinent questions to pose when designing a BDEPT concern the pharmacology of 
the prodrug and its corresponding API. Fundamental questions about the distribution 
pharmacokinetics of both drug and prodrug should be considered. It is crucial that these 
behaviours are adequately defined from the outset, because this will guide many of the 
ensuing steps of BDEPT design, including the correct alignment of the bacterial enzyme 
(Design Principle II), management of toxicological issues (Design Principle IV), and the 
selection of an appropriate bacterial carrier (Design Principle V) (Figure 2). The designer 
must know how easily their compound can infiltrate a cell by crossing the cell membrane. A 
prodrug will be converted to an API by the intracellular enzyme of a bacterium only if it can 
enter the bacterial cytoplasm. Furthermore, an API, which relies on direct engagement with 
intracellular tumour elements to function, must be present within a tumour cell for its 
mechanism of action to take hold. For example, 5-Fluorouracil (5-FU), an API commonly 
employed in BDEPT, acts as an inhibitor of deoxyribonucleic acid (DNA) and ribonucleic 
acid (RNA) synthesis only when it is processed intracellularly by mammalian enzymes [51].  
Pharmacokinetic properties can vary considerably between drug and prodrug. They can 
change so markedly upon activation that a prodrug which is capable of crossing cell 
membranes with ease can become impeded from doing so once enzymatically metabolised, 
thereby negating or reducing its capacity as a chemotherapeutic agent [14]. If an API is 
generated external to a tumour cell, and its cell membrane is impenetrable to the API, the 
drug will be unable to initiate its anticancer modality. In these scenarios, prodrug conversion 
must occur within tumour cells for therapy to be effective. Conversely, an API which crosses 
cell membranes easily can undergo activation extracellularly while retaining therapeutic 
efficacy.  
Fortunately, the properties of small-molecule drugs which alter their ability to cross cell 
membranes are well-known. The ‘Rule of 5’ is a popular predictive tool for determination of 
a drug’s permeability in vivo based on its physicochemical attributes [52]. Solubility affects a 
drug’s partition coefficient [53], while molecular size and charge can similarly influence its 
movement [54]. The chemical properties of the ideal small-molecule drug are delicately 
balanced and it must be ensured that no one property is disproportionate. For instance, 
lipophilicity encourages drug movement across cell membranes, while hydrophilicity 
















thus preferable for moving a drug inside a cell, an overly lipophilic compound is associated 
with a poor toxicological profile [56]. It is acknowledged that making an informed prediction 
of the path a compound is likely to take in vivo is highly complicated; thus, the use of various 
mathematical and computational techniques are advocated to combat this challenge [55]. The 
‘Rule of 5’, for example, sets upper limits on a compound’s lipophilicity (a logP no greater 
than 5) and molecular size (no more than 500 daltons) [54]. Additionally, physiologically-
based pharmacokinetic modelling attempts to improve prediction accuracy by accounting for 
the variability of living systems [57].  
There are several examples of BDEPT enzymes which introduce modifications to their 
prodrug substrates which disfavour their passage across cell membranes. Uracil 
phosphoribosyl transferase (UPRT), for instance, catalyses the conversion of uracil to uridine 
monophosphate, and converts 5-FU to 5-fluorouridine monophosphate which then disrupts 
RNA and DNA synthesis [58]. The activated form of 5-fluorouridine is phosphorylated and 
therefore its charge will impede membrane permeability. Similarly, thymidine kinase (TK) is 
a phosphotransferase that is utilised in BDEPT with the prodrugs ganciclovir (GCV) and 
acyclovir (ACV), phosphorylating them to inhibit DNA synthesis. This likewise results in a 
charged API, reducing transport across lipid membranes. However, phosphotransferase-based 
BDEPT has not proven to be ineffectual. Bifidobacterium infantis has been engineered to 
express TK derived from the herpes simplex virus type 1 (HSV-1), and significantly arrested 
the growth of murine bladder tumours following administration of GCV [59].  
On the other hand, some enzymes can introduce favourable changes. For example, cytosine 
deaminase (CD) converts 5-fluorocytosine (5-FC) to 5-FU via the pyrimidine salvage 
pathway. 5-FU has lipophilic properties which are conducive to its movement across cell 
membranes. Following the first report of CD expression in Bifidobacterium longum [60], 
CD-BDEPT has since been tested preclinically with various bifidobacterial species. B. 
longum expressing CD was used to localise prodrug conversion to autochthonous mammary 
tumours in rats, with corresponding antigenicity studies in guinea pigs confirming low 
immunogenicity [61]. B. breve was later found to more stably express the enzyme in vitro, 
showing 3- to 6-fold greater enzymatic activity than that of B. longum [62]. Non-
bifidobacterial species have also been used to express CD. Preclinical in vivo studies in 
rhabdomyosarcoma-bearing rats showed that intratumoural injections of Clostridium 


















Design Principle II: Orientation of the Enzyme  
Bacteria, being living entities, may be subject to the same drawbacks of chemotherapeutic 
agents as human cells, including their accessibility to small-molecule compounds. This 
limitation can be addressed by manipulation of the enzymology of the BDEPT. The 
enzymatic reaction is the central event by which drugs are modified chemically in BDEPT. If 
chemical modifications of drugs bring about their activation, and impact their movement 
between extracellular and intracellular compartments, the designers of BDEPT must therefore 
understand the enzymology of their design, and how it could alter the pharmacodynamics and 
pharmacokinetics of a compound.  
The biochemistry of GDEPT enzymes is known in detail [64, 65]. The design of GDEPT 
prodrugs and the pharmacology of their active forms are also well-known [66]. Despite the 
extensive range of enzymes used in GDEPT [67], the variety of BDEPT enzymes is 
comparatively low (Table 1). Presumably, this is because GDEPT, and its various offshoots 
such as antibody-directed enzyme prodrug therapy (ADEPT), are older styles of gene therapy 
[68]. It could also be the case that because many GDEPT enzymes are mammalian, without 
prokaryotic counterparts, their application in bacterial carriers is more complex.  
 
Table 1. Examples of enzyme-prodrug strategies, their mechanisms of action, and the bacterial 
carriers with which they are associated. 
Bacterial Carrier Enzyme Prodrug Mechanism of 
Action 
Reference 
B. longum CD 5-FC 












Range of aromatic nitrogen 
mustard prodrugs 
DNA cross-linking [71] 
























Listeria monocytogenes CD/PNP/UPRT 5-FC 





















The placement of the selected enzyme within a bacterial carrier is critical. If the enzyme 
requires reducing conditions or cofactors (e.g. NTR [76]), it should be expressed in the 
cytosol. However, a bacterium expressing a cytoplasmic, prodrug-modifying enzyme can 
activate a prodrug only if both are simultaneously present in the bacterial cell. An API 
without an aptitude for crossing the cell membrane may become trapped inside the bacterium 
after it is activated. If the prodrug itself is hydrophilic, it may not be able to enter the cell in 
the first place. This problem can be negotiated by tethering the enzyme to the cell wall of 
Gram-positive bacteria, or the outer membrane of Gram-negative bacteria using leader 
peptides and transmembrane sequence systems [12], or by re-routing it to the periplasm – a 
protein rich boundary found in the bacterial cell wall [77]. There are numerous examples of 
enzymes which have been subjected to this method in Gram-negative bacteria, including 
CPG2 and β-G (Figure 3). 
CPG2 is a dimeric protein, derived from Pseudomonas sp. RS-16, that can remove a 
deactivating glutamate moiety from a range of mustard prodrugs [78]. This results in the 
formation of potent DNA cross-linking agents with high cytotoxicity differentials between 
drug and prodrug. Cytoplasmic CPG2 has not proven to be very efficacious, most likely 
because the prodrugs relevant to CPG2 are hydrophilic, and the enzyme naturally resides in 
the periplasm of Pseudomonas sp. RS-16. Periplasmic CPG2 has thus been investigated to 
confront this issue. CPG2 has been directed to the periplasm of VNP20009 via the ompA 
signal peptide, and was effective in activating many mustard prodrugs. This construct was 
tested with human breast and colon carcinoma cell lines, resulting in retarded tumour growth 
[71]. 
The hydrolytic activity of β-G is capable of rendering several drugs active, including phenol 
mustards and anthracyclines [79]. The enzyme has been experimentally expressed in E. coli 
DH5α cells, with results indicating inferior activation of irinotecan, a topoisomerase 
inhibitor, by the bacterial carrier compared with an adenoviral carrier expressing the same 
enzyme [80]. One of the reasons put forth to explain this observation was that the enzyme of 
E. coli DH5α was placed in its periplasmic space, and was therefore less accessible than the 
adenoviral enzyme which was delivered to the membranes of virally-infected cells. β-G has 
been directed to the outer membrane of E. coli BL21 by fusing it with an autotransporter 
















inducing toxicity in experimental human colon cancer cells [81]. 
 
Figure 3. Enzymatic alignment strategies in BDEPT. An illustration of the various 
enzymatic conformations that have been investigated in BDEPT. The activation of 
hydrophilic prodrugs has been enhanced by coupling BDEPT enzymes to the surface or 
directing them to the periplasm of Gram-negative bacteria (e.g. E. coli BL21 and VNP20009, 
respectively). 
Augmenting an enzyme’s exposure to the prodrug by relocating it closer to the cell surface 
could possibly impact the stability of the enzyme itself. Some enzymes exhibit contrasting 
biochemistry when their expression is switched from cytoplasmic to periplasmic to surface-
bound conformations. β-galactosidase, for example, is rendered toxic when exposed to the 
periplasm of E. coli [82]. On the other hand, the reduced quantity of proteases in the 
periplasm compared with the cytoplasm [83] may favour enzymatic stability in the 
environment of the former.  
 
Design Principle III: Optimisation of Enzyme Kinetics  
A central goal of BDEPT is to design a therapy with a high kcat / KM ratio. This ratio is 
commonly used to compare the kinetics of a single enzyme across multiple substrates, or to 
compare the kinetics of single substrate against multiple enzymes [84]. With BDEPT, both 
















be desired and this requires reworking of either the enzyme or its substrate to ameliorate 
overall reactivity. Early efforts of enzyme optimisation include the mutagenic adjustments 
made to the HSV-1 TK [85]. Optimisation of this enzyme is needed because its unaltered 
form has a high KM for ACV, and because GCV is immunosuppressive at therapeutic doses. 
A library of mutated TK enzymes was screened for improved kinetics, identifying three 
mutants which, when tested in vitro in a rat glioma C6 cell line, greatly increased the 
sensitivity of the cell line to GCV and ACV compared with native HSV-1 TK.  
Enzyme kinetics are relevant also to CD. CD is not found in mammalian cells found but it is 
found naturally in the cytoplasm of bacteria [86]. Thus, bacteria which inhabit the human 
intestinal tract, and express the enzyme, can activate prodrug substrates with which they 
come into contact [87]. Wildtype CD has a relatively high KM value for its prodrug substrate 
5-FC than it does for cytosine [88], which warrants high doses of prodrug for BDEPT to be 
efficacious. This elicits undesirable, off-target toxicity.  
The kinetics of CD have been revamped via mutagenic alterations. Amino acid substitution of 
regions lining the active site of CD has resulted in the identification of a CD variant with 
improved kinetics over the native enzyme in a xenograft tumour model [87]. Similarly, a 
shuttle plasmid incorporating CD with a mutation in its active site has demonstrated a 10-fold 
improvement in its kinetics over prior attempts [89]. Ideally, enhanced CD kinetics will help 
to overcome the impediments which are obstructing CD-BDEPT from the clinic, such as the 
rapid elimination of 5-FC from the systemic circulation and insufficient gene delivery.  
The NTR family of enzymes has likewise been scrutinised for improved kinetics. NTR was 
among the first enzymes implicated in BDEPT, in conjunction with Clostridium beijerinckii 
[69, 90]. NTR activity is evident in anaerobic bacteria commonly found in the gastrointestinal 
tract [91]; thus, as with CD, prodrug substrates for NTR may cause non-specific toxicity 
when they are administered. The native NTR enzyme NfsB of E. coli can reduce the weak, 
alkylating 5-(aziridine-1-yl)-2,4-dinitrobenzamide prodrug CB1954 to potent DNA-
intercalating agents, using NADH or NADPH as a cofactor [92]. NfsB was originally the 
most widely studied prodrug-activating NTR [93]. However, wildtype NfsB is kinetically 
unimpressive with multiple prodrugs [94, 95] and its high KM has inspired research into 
alternative enzymes with better kinetic properties, such as NfsA. NfsA has demonstrated a 
















As CB1954 is hepatotoxic when metabolised by the liver [97], setting tighter upper limits on 
doses of this prodrug is desirable. Other strains of bacteria, apart from E. coli, have been 
searched for the presence of NTR enzymes with improved kinetics that could allow dose 
reductions of CB1954. A fluorogenic probe was used to identify the flavin reductase MsuE, 
from P. aeruginosa, which exhibited a kinetically similar aptitude to the NfsA of E. coli in 
vitro for the reduction the next-generation DNA cross-linking 3,5-dinitrobenzamide-2-
mustard prodrug PR-104A, and the next-generation nitrochloromethylbenzindoline prodrug 
CBI-DEI [98]. Furthermore, the NfsB enzyme of P. aeruginosa has recently been described 
for its improved kinetics in vitro over the NfsB enzyme of E. coli for reduction of CBI-DEI 
[95]. The newly-discovered enzyme NmeNTR, derived Neisseria meningitidis, has the 
advantage over the NfsB enzyme of E. coli in that it reduces CB1954 purely to the toxic 4-
hydroxylamine derivative, whereas NfsB produces equimolar concentrations of the 4-
hydroxylamine derivative, and the less toxic 2-hydroxylamine derivative [99]. 
Screening of NTR enzymes has led to the finding of more kinetically advanced NTR-BDEPT 
systems, which may allow dose reduction of CB1954. An oxioreductase library has been 
generated and screened using E. coli SOS reporter strains to quantify activation of CB1954 
and PR-104A by NTR enzymes [100]. The in vitro sensitisation of E. coli cells to the 
activated prodrugs was used to evaluate enzyme efficiency. This led to the discovery of 
YcnD_Bs, which has a higher kcat / KM ratio than NfsA. It also led to the discovery of 14 
reductases with higher kcat / KM ratios than NfsB_Ec, which up until that point was the most 
active PR-104A reductase.  
As with CD, an effort has been made to forge mutated versions of NTR with better kinetics 
[101]. An E. coli SOS reporter strain was used to identify another flavin reductase, FRaseI 
from Vibrio fischeri, which displays better kinetics than NfsB in vitro in HCT-116 human 
colon carcinoma cells lines, and was further improved via site-directed mutagenesis [102]. 
Directed evolution, again using an E. coli SOS reporter system, has produced an NfsA variant 
with a higher affinity for PR-104A than native NfsA of E. coli, inducing higher drug 
sensitivities in human cell lines and mouse xenografts [103]. Moreover, a codon optimisation 
strategy was implemented with C. sporogens to heighten its ability to stably express NTR 
enzymes derived from E. coli [104]. Resultantly, doses of CB1954 and PR-104A, which were 
sub-therapeutic prior to codon optimisation, exhibited therapeutic potential thereafter in 
















Another approach to increase the kcat / KM of an enzyme is to manufacture better substrates 
for that enzyme. Novel prodrugs have been synthesised in the interest of developing better 
substrates for NTR. For example, 6-chloro-9-nitro-5-oxo-5Hbenzo(a)phenoxazine (CNOB) is 
a prodrug that can be converted by the enzyme ChrR6 to the cytotoxic and fluorescent agent 
9-amino-6-chloro-5H-benzo(a)phenoxazine-5-one (MCHB) [105]. MCHB has been used 
with the non-virulent Salmonella strain SL7838 to treat murine tumours. Impressive 
remission rates were seen in mice implanted with tumours endogenously expressing ChrR6, 
following administration with CNOB. Unfortunately, only 10% of the mice treated with 
SL7838-ChrR6 survived after 60 days of treatment, implying that a defect was present in 
some facet of the BDEPT, possibly related to unsatisfactory availability of the bacterial 
enzyme to the prodrug.   
 
Design Principle IV: Toxicity of the Prodrug/ PI to the Bacterium 
Although BDEPT is designed to mitigate off-target toxicity to healthy tissues, the toxicology 
of the activated drug is still relevant. A chemotherapeutic drug which damages healthy and 
cancerous human tissue potentially poses a threat to the viability of bacterial cells. However, 
not all drugs will affect bacterial survival [106]. Studies with VNP20009 suggest that 
hydrophilic APIs are only harmful to the bacterium if, following activation outside the cell, 
the cell membrane is destabilised and the drug leaks into the bacterial cytoplasm [107]. If the 
drug is activated in the periplasm of the bacterium and is too hydrophilic to cross its inner 
membrane, the API will not harm bacterial DNA even if the enzyme is over-expressed.  
The molecular differences between prokaryotic and eukaryotic cells are significant in that 
they may allow the mechanisms of action of chemotherapeutic cancer drugs to solely target 
mammalian cell machinery (the same principle holds in reverse to many antibacterial 
therapies, like penicillin, which relieve patients of unpleasant side effects by homing in on 
prokaryotic cellular peculiarities). The topoisomerase I inhibitor 9-aminocamptothecin (9-
AC), for example, targets a topoisomerase enzyme chiefly expressed in mammalian cells 
[108, 109]. Hence, it should not pose a toxicological threat to bacteria. E. coli DH5α has been 
employed to deliver β-G to experimental tumours [72]. Here, the prodrug 9-ACG was 
administered, which is hydrolysed by β-G to 9-AC. Importantly, 9-AC did not destroy the 
bacterial vehicle, and in vivo, the combined treatment hampered CL1-5 human lung tumour 
















Some chemotherapies, however, can damage bacteria. A recent study catalogued the effects 
of various chemotherapeutic agents on lactic acid and bifidobacterial strains, indicating the 
sensitivity these strains have towards antimetabolite drugs like 5-FU and doxorubicin [110]. 
2-fluoroadenine, a metabolite of fludarabine (Figure 4), has antibacterial properties [111]. 
PNP, the enzyme which catalyses the conversion of fludarabine, can break down non-toxic 
deoxyadenosine molecules into highly toxic adenine analogues [112]. The endogenous PNP 
enzyme of Salmonella (genetically homologous to the PNP of E. coli) has been exploited to 
convert 6-methylpurine-2-deoxyriboside (6MeP-dR), a substrate for bacterial PNP but not 
human PNP, to 6-methylpurine (6MeP). In vivo, murine B16F10 tumour growth was 
diminished following this regimen [74]. Though the inhibition of DNA synthesis instigated 
by these toxic molecules results in tumour cell death, bacterial viability too may be affected. 
This may partly explain why adenoviral PNP delivery has enjoyed success in phase I clinical 
trials [113], while PNP-BDEPT has yet to be tested in patients. 
Our studies of CB1954 revealed that bifidobacterial strains and certain E. coli strains (e.g. 
MG1655) are highly sensitive to the prodrug, whereas other E. coli strains (e.g. E. coli Nissle 
1917) and Lactococcus are more resistant. Western blot studies of NTR suggest that high 
concentrations of NfsaA and NfsB are responsible for the toxicity of CB1954 to bacteria. The 
activated forms of CB1954 are a mixture of 2- and 4-hydroxylamines, of which the latter is 
the more effective DNA cross-linker (Figure 4). The hydroxylamine compounds to which 
CB1954 is metabolised are mutagenic and are inhibitory to bacterial DNA, RNA, and protein 


















Figure 4. Toxic metabolite production via BDEPT enzymes. Fludarabine is converted by 
PNP to 2-fluoroadenine (C5H5N5F), while CB1954 is converted by NTR to DNA cross-linking 
agents, all of which are potentially deleterious to bacteria via inhibition of DNA, RNA, and 
protein synthesis. 
 
Toxicity issues can be worked against by enzymological adjustment of a BDEPT. While it is 
a feasible tactic for enriching the activation of a hydrophilic prodrug, re-orientation of an 
enzyme such that it is closer to the surface of the bacterial cell can also be applied to 
circumvent toxicological threats to bacteria. Again, the implications of engineering the 
enzyme and possibly affecting its activity, as well as the distribution pharmacokinetics of the 
API, should be borne in mind. A lipophilic, toxic API, despite being activated in a non-
cytoplasmic region, may nevertheless cross into the cytoplasm of the bacterial cell, exerting a 
















membrane permeability of their compound, because this will clarify whether re-calibration of 
the enzyme will be truly beneficial to BDEPT efficacy  
 
Design Principle V: Choosing a Bacterial Carrier 
At this stage, having defined the pharmacological and toxicological traits of both drug and 
prodrug, and having gained an appreciation of the biochemistry of their chosen enzyme, the 
designer should be able to deliberate on an appropriate bacterial carrier. This decision should 
integrate four separate considerations: the level of invasiveness desired of the bacterium, the 
appropriateness of a wildtype carrier versus a recombinant carrier, the advantages offered by 
Gram-positive versus Gram-negative bacteria, and facultative versus obligate anaerobic 
bacteria. 
(i) Intracellular vs. Extracellular Bacterial Carriers 
In BDEPT, the bacterium must be positioned such that it is capable of enzymatically 
activating its prodrug target. If prodrug metabolism is to occur within the tumour cell, the 
bacterium will require intracellular access to supply its enzyme, but the requirement is 
waived if the drug can enter the cancer cell following activation. ‘Bactofection’ is the 
bacterial equivalent of transfection, whereby an invasive bacterium is engineered with a 
plasmid featuring a transgene under the control of a mammalian promoter which, following 
administration, invades the host, lyses, and releases the plasmid within the host’s cells [116]. 
The plasmid migrates to the host cell’s nucleus where the transgene can be transcribed. This 
procedure typically relies on disease-causing bacterial strains, presenting safety concerns in 
terms of off-target toxicity and immune stimulation [19]. An example of bactofection 
involves exploitation of attenuated L. monocytogenes administered to murine tumours in vivo, 
and human breast tumour tissues ex vivo [116]. The microbial cells were sensitive to 
ampicillin and were ruptured following systemic administration of the antibiotic. This caused 
the release of plasmid DNA, and the subsequent expression of a lysin transcribed by a 
mammalian promoter. Additional cell lysis occurred due to heightened expression of the lysin 
itself.  
In BDEPT, bactofection can be applied if the API has difficulty crossing cell membranes, if 
the enzyme cannot be expressed inside bacterial cells optimally, or in a ‘host cell conditional’ 
















pathogenic bacteria have been engineered to confer upon them invasive qualities. For 
example, the bacterial designer strain Escherichia coli BM2710 was engineered to express 
two genes to formulate an invasive strain: the inv gene from Yersinia pseudotuberculosis 
which facilitates invasion of mammalian cells that express the β1-integrin, and the hly gene 
from Listeria monocytogenes, which induces phagosomal escape and the release of bacterial 
cytoplasmic proteins and plasmid DNA into the cytoplasm of mammalian cells [117].  
Bactofection has been incorporated into several BDEPT designs to internalise drug activation 
in the target cell. This overcomes the drawback of enzymes like PNP and TK, which 
phosphorylate their targets, thereby impeding their movement into cells. L. monocytogenes-
mediated bactofection has delivered PNP into several tumour cell lines, allowing efficient 
cytotoxicity [75], while attenuated Salmonella has been employed to deliver TK to 
experimental B16 melanoma cells in vivo in which, following GCV administration, 
significant suppression of tumour growth was observed [73]. 
Anticancer therapies which rely on intracellular agents to deliver genes to tumours generally 
fall drastically short of depositing their payload in the entirety of the malignancy [9, 118]. 
The bystander effect is critically important for these intracellular agents. The bystander effect 
hinges on the idea that tumour cells which do not acquire the gene of interest may 
nevertheless be affected by downstream events resulting from its expression in other cells. 
Within the context of BDEPT, these downstream events refer to the passage of prodrugs into 
tumour cells containing the gene of interest, and the passive or active translocation of 
cytotoxic metabolites into local cells or distant tumours [67]. An understanding of the 
bystander effect is an essential part of predicting the efficacy of BDEPT mediated by 
intracellular bacteria. The importance of the bystander effect is evident in a study in which an 
attenuated strain of S. typhimurium was used to deliver PNP in vitro to murine Lewis lung 
carcinoma and melanoma cells [119]. Significant reductions in cell survival were observed, 
even in cases where only 1% of cells tested positive for the carrier.  
The impact of the bystander effect can be magnified, often by the use of kinetically-superior, 
mutated [87] or naturally-occurring enzymes [96], or alternative prodrugs [95, 120]. The in 
vitro measurement of the bystander effect is sensitive to the type of cell line analysed [118]. 
Multilayer and spheroid cell lines are advocated for their stronger resemblance to the tissue 
















effect is intertwined with therapeutic efficacy; thus, an increase in its magnitude will permit 
dose reductions of administered prodrugs. 
 
(ii) Recombinant vs. Wildtype Bacterial Carriers  
It is recommended that bacterial recombination of enzyme-coding genes should take place 
within chromosomal DNA rather than within plasmid DNA [99]. Not only does chromosomal 
integration increase the stability of transgene expression, but chromosomes are not 
considered ‘mobile genetic elements’, and are not known to partake in horizontal gene 
transfer from one bacterium to another, unlike plasmids [121]. In this way, translocation of 
genetically-engineered material between microorganisms in vivo is reduced, which is of great 
significance to the regulators of recombinant investigational medicinal products (see later). 
Bacteria that have been engineered to express heterologous genes at high levels can 
synthesise enzymes in large quantities [122]. However, recombinant bacteria are liable to 
suffer from a metabolic burden resulting from gene overexpression. This burden originates 
from a divergence of the microbe’s cellular resources so that transgene expression can be 
maintained. This can overload the carrier and disrupt its targeting capacity due to loss of its 
transgene and compromised viability [123]. Transgene expression can be negated due to 
spontaneous loss of plasmids [124, 125]. In this case, the survival of genetically-
unencumbered microbes which have lost their transgene is favoured, while recombinant 
bacteria are eventually eliminated by natural selection. 
If recombinant gene overexpression is a potential threat to the integrity of the bacterial 
carrier, this problem could be alleviated by exercising stricter control over bacterial enzyme 
production. Burdensome recombinant gene expression reduces the pliability of BDEPT 
carriers, as it complicates the production of appropriate levels of enzyme. E. coli, for 
instance, possesses natural proteolytic facilities to counteract the overexpression of proteins 
which do not benefit its survival [126]. This problem can be manoeuvred by using protease-
deficient or heat shock-deficient strains, for example. An excessively taxed bacterium, 
deprived of amino acids due to transgene expression, could also be supplemented with 
exogenous amino acids to correct the depletion. 
Putting genetically-engineered, recombinant bacteria aside, the BDEPT designer could also 
















enzymes. Wildtype bacterial cells, by definition, tax themselves according to what is required 
by their default cellular needs, and are not expected to mobilise additional resources to 
produce foreign biomolecules. This means that the expression of prodrug-converting 
enzymes by wildtype bacteria could overstep the disadvantages of using recombinant strains, 
because natural expression would be less likely to affect the integrity of the carrier. Wildtype 
bacteria have been used to activate different prodrugs. Our laboratory has successfully 
employed the prodrug fludarabine in conjunction with the endogenous activity of E. coli 
Nissle 1917 to induce cancer cell death in multiple cell lines [106, 127]. We have reported 
that several species of bacteria can activate CB1954 with a natural enzymatic complement, 
and have shown that it is possible to activate multiple prodrugs concurrently (5-FC, CB1954 
and fludarabine), presenting opportunities for treating refractory tumours with more than one 
prodrug. Interestingly, prodrugs can be activated without a known corresponding enzyme, 
suggesting that wildtype bacteria have an ‘enzymolome’ that could be harnessed to activate 
drugs for cancer therapy. For instance, the drug AQ4N can be activated by E. coli Nissle 
1917 in vitro to kill cancer cells, although the mechanism of activation is unknown.  
While the notion of delivering a carrier with a diverse enzyme reservoir to a tumour appears 
auspicious in terms of prodrug activation and therapeutic efficacy, our lab has detailed a 
range of prodrugs frequently used in mainstream chemotherapy that can be deactivated by 
bacterial enzymes, including etoposide phosphate, cladribine, and gemcitabine [127]. This is 
not unexpected as a bacterium’s enzymolome is vast and may harbour enzymes which 
deactivate certain drugs while activating others. This clinically relevant phenomenon ought to 
be addressed by the designer irrespective of whether they integrate a recombinant or wildtype 
strain into their design.   
 
(iii) Gram-Positive vs. Gram-Negative Bacterial Carriers 
When selecting a bacterial carrier, it is helpful for the designer to contemplate the influence, 
both physical and biochemical, of inner and outer bacterial membranes on prodrug activation. 
This necessitates discussion of Gram-positive and Gram-negative bacteria, which differ from 
each other in the constitution of their cell envelopes. The cytoplasm of both Gram-negative 
and Gram-positive bacteria is separated from the extracellular environment by a cell 
envelope. In Gram-negative bacteria, this consists of an outer membrane and an inner 
















in Gram-positive bacteria, an outer membrane is lacking, and the existence of a Gram-
positive periplasm is less noted, although it has been described [128-130]. This should be 
taken into consideration when mapping-out a BDEPT design. The differences between Gram-
positive and Gram-negative cell envelopes have implications for bacteria in terms of the way 
they interact with their host, and their flexibility as a BDEPT carrier.  
Examinations of VNP20009 have revealed the affliction that Gram-negative bacteria can visit 
upon their host. Lipid A, which forms part of the lipopolysaccharide (LPS) component of the 
outer membrane, can provoke toxic shock syndrome in the organisms they inhabit [131]. A 
convenient workaround for this obstacle involves deleting the bacterial gene msbB, which 
abolishes the toxicity of lipid A [132, 133]. LPS plays another role by decreasing the 
permeability of the outer bacterial membrane, although mutations in msbB do not appear to 
affect the structural integrity of this barrier [134].  
With Gram-negative bacteria, the outer membrane represents a supplementary blockade 
against the admission and escape of prodrug and API to and from the cell, limiting the 
passage of large, charged molecules, but letting hydrophilic molecules in through porin 
channels [135]. Lipophilic molecules are less prone to crossing the outer membrane than the 
inner membrane, probably because of the comparatively disordered arrangement of the inner 
membrane’s lipid content [136]. Overall, the multi-layered, multi-functional barrier that is 
unique to Gram-negative bacteria complicates the migration of both hydrophilic and 
lipophilic drug molecules due to the inner and outer bacterial membranes, respectively.  
 
(iv) Oxygen Tolerance of Bacteria 
Differences in oxygenation between tumour tissue and healthy tissue, and even between 
different parts of the tumour itself [137], is a foundational aspect of tumour-selective 
colonisation by bacteria. Selectivity occurs because the hypoxia that is evident in tumours 
does not materialise as severely in healthy tissues [20]. The selective colonisation of necrotic, 
hypoxic tissue by anaerobic bacteria is viewed as advantageous, because it permits access to 
parts of tumour tissue that are notoriously hard to penetrate using standard chemo- and 
radiotherapy [47].  
There are drawbacks of exclusive necrotic tissue colonisation that ought to be noted. An 
















prodrugs which are chiefly delivered to oxygenated tissues [137]. Alternatively, a flexible 
facultative anaerobic bacterium which can acclimatise to varying grades of oxygenation will 
be better placed than an obligate anaerobe to promote maximal prodrug activation at its 
intended site of action. One might expect this flexibility to come at the price of potential 
colonisation of more oxygenated extra-tumoural tissues and consequential systemic toxicity, 
however both obligate and facultative anaerobic bacteria display similar tumour-to-liver 
colonisation ratios [32, 138].  
While facultative anaerobic bacteria are, in theory, more likely to inhabit more diverse 
tumour regions than their obligate anaerobic brethren, their adaptability is not assured. S. 
typhimurium, for example, has been shown to colonise only necrotic regions of murine 
tumours, despite being a facultative anaerobe [35]. An auxotrophic variant of this same 
bacterium has since been engineered and observed to grow in both viable and necrotic tissue 
[30]. It is important to be cognisant that different auxotrophic modifications can be used to 
influence such bacterial platforms in different ways; for example, in the case here the 
mutation increases the range of tumour tissue within which the bacterium can grow (due to 
oxygen-related metabolic activity) while in other cases, auxotrophic mutations restrict where 
a bacterium may survive. 
 
Improving BDEPT R&D with Tools for Monitoring Bacterial Enzymatic Activity 
The defining reason for failure of oncological medicines in late stage clinical trials is a lack 
of therapeutic efficacy [139]. One of the causative factors may include insufficiencies in the 
technologies available for therapeutic drug monitoring in vivo. These technologies could help 
familiarise investigators with the in vivo agency of elusive, novel medicines like BDEPT.  
For gene therapies in particular, the Recombinant DNA Advisory Committee of the National 
Institutes of Health recognises the need for reliable assays of transgene expression, and 
quality control of gene therapy carrier trafficking [140]. Blood sampling and tissue biopsies 
are invasive, periodic, and retrospective, and introduce convolution into the procedure [141]. 
Contemporary standards therefore demand non-invasive, real-time facilities for continuous 
assessment of transgene expression and therapeutic efficacy. The availability of a high-
calibre facility for monitoring the progress of a medical intervention is correlated with an 
accelerated bench-to-bedside timeframe [142], so it is worthwhile reflecting on how BDEPT 
















For the BDEPT designer, real-time monitoring of the impact of the bacterial carrier and 
prodrug administration on tumour regression is an invaluable way of evaluating 
responsiveness to a medical intervention. The unique features of BDEPT offer the designer a 
special and convenient vantage point for surveillance of the course of treatment. The selective 
colonisation of tumour tissue by bacteria, and the resultant enzyme expression, can be utilised 
to fashion a prodrug-like compound into an imaging probe. In this setting, the probe is 
attached to a signal quencher which, when enzymatically cleaved, emits a detectable signal 
which can be observed in vivo using imaging techniques. Thus, a prodrug which is visually 
detectable when activated by a bacterial enzyme is indicative of transgene expression. A 
further potential benefit of this strategy involves the generation of data indicating the location 
and size of a malignancy.  
Readouts can be produced via molecular imaging (MI) techniques, such as optical imaging 
(OI), positron emission tomography (PET), and magnetic resonance imaging (MRI) [143]. 
For preclinical imaging, OI represents the most feasible method for researchers in terms of 
accessibility, however, PET and MRI are more informative approaches for determination of 
clinical activity, and aid the formation of a complete diagnostic picture [144, 145]. Several 
imaging modalities exist for non-invasive visualisation of bacterial enzymatic activity [36, 
146, 147]. Critical proof-of-concept issues can be tackled by adoption of these technologies, 
including quantification of bacterial growth, assessment of intratumoural growth patterns, and 
confirming whether tumour-specific growth has occurred at all. 
Various dyes exist which are reduced to their fluorescent form by NTR. These include the 
redshifted, quenched fluorophore, CytoCy5S, which is reduced to its fluorescent form by 
NTR [148, 149]. We have shown this probe to be useful in tracking the location of tumour-
targeting bacteria in vitro and in vivo. [150, 151] VNP20009, expressing TK, has been 
engineered to enable its visualisation in C38 colon and B16-F10 melanoma tumours in mice 
[152, 153]. The radiolabelled nucleoside analogue 2'-fluoro-1-beta-D-arabino-furanosyl-5-
iodo-uracil (FIAU), following VNP20009-TK-mediated phosphorylation to sequester it 
within tumours cells, allowed visualisation of bacteria in vivo by PET and autoradiography. 
Bacterial proliferation in tumours could be easily monitored, as radioactivity levels correlated 
with the numbers of bacteria present. Similarly, CPG2 activity has been monitored in vivo, in 
a xenograft murine tumour model, using the 
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While CytoCy5S, FIAU, and 3,5-DFBGlu are advantageous in that they permit monitoring of 
enzymatic activity, they are not therapeutic with respect to tumour growth inhibition. Several 
compounds have been synthesised which function as both therapeutic and monitoring agents. 
CNOB, for example, is converted into MCHB, which is both fluorescent and cytotoxic [105]. 
Moreover, the conversion of 
19
F-labelled 5-FC into cytostatic 5-FU by VNP20047 expressing 
CD as a reporter gene has enabled visualisation of murine tumours in vivo in a human 
HCT116 colon tumour xenograft by magnetic resonance spectroscopy (MRS) [155].  
BDEPT enzyme activity may also be examined in ex vivo samples through indirect methods 
which assess for the presence of activated probes within the sample (Figure 5). Such 
strategies have also been proposed as potential cancer diagnostics, in that they may reveal the 
presence of a tumour within the body due to their acting as a readout for administered 
bacteria which have colonised malignant tissue. For example, E. coli expressing a regulated 
lacZ gene was designed to detect experimental liver metastases [156]. Following bacterial 
colonisation of hepatic tumours in mice, the bacterial lacZ device was induced by 
systemically administered isopropyl β-D-1-thiogalactopyranoside. Subsequently, a caged 
luciferin probe was administered, cleaved, and activated by lacZ, and renally-excreted. Urine 
samples were quantified by emission of light for the presence of luciferin, facilitating quick 
and non-invasive cancer detection. In a similar fashion, Panteli et al. created an inducible 
biomarker module that can be detected in blood samples by antibodies using a type of 
enzyme-linked immunosorbent assay [157]. The biomarker, ZsGreen, was expressed by 

















Figure 5. BDEPT enzymatic activity detection. Therapeutic enzymatic activity may be 
detected in situ, or ex vivo. Direct in vivo detection can be accomplished by activation of a 
light-emitting probe by bacterially-expressed enzymes at the site of the tumour, followed by 
MI to acquire an image of the probe. Indirect detection may be achieved by analysis of blood 
or urine samples for probes that have been activated by bacterial enzymes in the tumour and 
secreted into the circulation. 
 
Barriers to the Clinic  
Several examples of clinically-trialled BDEPT exist; however, the regulatory requirements 
necessary to make a breakthrough, regulated medicine of this kind have yet to be satisfied. It 
may be insightful to review the clinical progress achieved thus far with this therapy. The 
reasons for the absence of BDEPT from the clinic are probably multi-faceted, and the way in 
which designers comprehend and confront the barriers to the clinic will dictate how readily 
access to it is granted.  
CD-BDEPT has been tested in phase I clinical trials with VNP20009 [25]. Data were 
collected for 25 patients – 24 patients with melanoma, and one patient with metastatic renal 





resulted in low levels of tolerance in patients, and only 3 patients had tumours in 
















patient. Trial investigators noted that preclinical studies in mice were not reflective of what 
was witnessed clinically, and speculated about host-specific differences between murine and 
human tumour composition that could affect colonisation of bacteria in malignant tissue. 
Following publication of the data for the phase I clinical trial, an update was issued 
describing the administration VNP20009 in four additional melanoma patients [27]. Results 
mirrored those of the pivotal study, with no patient achieving a significant clinical response.  
After the phase I clinical trial of VNP20009, a pilot clinical study of CD-BDEPT was 
conducted with VNP20009. This was narrower in scope than the pivotal study, recruiting 
three patients with head and neck cancer. [158]. Notably, the gene for CD was 
chromosomally integrated into VNP20009 to increase therapeutic efficacy. Intratumoural 
injections of VNP20009-CD resulted in persistence of bacteria in two of these patients, 
bringing about the conversion of 5-FC to 5-FU at the patients’ tumour sites.  No significant 
measurements of 5-FU were made systemically. Even so, no tumour regression was observed 
in either patient and the trial was discontinued. This was a disheartening conclusion to 
encouraging preclinical data. King et al. had previously demonstrated efficacy in murine 
tumours using VNP20009 harbouring CD in which an 88-96% inhibition of tumour growth 
was observed in mice treated with VNP20009-CD and 5-FC compared with 38%-79% 
inhibition achieved with VNP20009-CD alone [159]. 
The results of the pilot and pivotal clinical trials of VNP20009-CD call for an explanation as 
to why tumour colonisation patterns differ between murine models and human subjects. 
Taken together, two factors appear to be common to both studies: poor enzymatic activation 
of 5-FC and poor colonisation of tumour tissue by VNP20009. It cannot be overlooked that 
the lacklustre kinetics of wildtype CD, referred to earlier, may explain why human trials of 
VNP20009-CD have so far returned with disappointing results in terms of inadequate tumour 
regression in tumour-colonised patients. Furthermore, as mentioned previously, colonisation 
of VNP20009 within tumours tends to be compartmentalised within necrotic regions, which 
are distinct from the viable zones of tumour tissue into which prodrugs are primarily 
delivered. A review of the literature reveals various efforts which endeavour to address these 
problems. The identification of auxotrophic VNP20009 mutants and more efficient CD 
variants, referenced above, are clear attempts to improve tumour colonisation and tumour 

















Recently, a transformed strain of B. longum (APS001F), containing a point mutation in its 
CD gene, was described as having 10-fold greater enzymatic activity in vitro than its 
wildtype counterpart [160]. It subsequently demonstrated significant inhibition of tumour 
growth in murine models following 5-FC administration, and is the subject of a phase I/II 
clinical trial presently enrolling oncology patients (clinicaltrials.gov identifier: 
NCT01562626). Results from this trial are eagerly awaited, and may shed light on the effects 
of enzyme optimisation on the therapeutic efficacy of BDEPT.  
Beyond therapy-associated parameters potentially responsible for inconsistencies between 
clinical and preclinical findings, external causes of disparities could be traced to the 
properties of the animal model used. A ‘quick win, fast fail’ approach is advised in research 
and development (R&D), by which the viability of a product is determined at the earliest 
possible stage [161]. Acquiring insights into product inadequacies at the preclinical stage 
allows for expedited curtailment of failing R&D projects, thereby improving R&D 
productivity. Of course, the choice of an appropriate preclinical model which is the most 
illustrative of the clinical reality is an indispensable part of this process. 
There has been a recent reallocation of interest to non-murine animal models, such as canine 
models, which may be more representative of a human response to cancer treatment [162, 
163]. The use of naturally-occurring tumours in companion dogs has been examined for the 
benefits it offers over artificially-induced tumours in mice for predicting clinical response. 
The genetically heterogenous character of spontaneous tumours in canines keeps more 
closely to the disparate nature of human malignancies than the artificial tumours of inbred 
mice, which have more a more homogenous make-up. Additionally, the circulatory system of 
dogs more closely resembles that of humans in terms of blood volume. The more expansive 
blood supplies of humans, compared with mice, can reduce bacterial colonisation within 
tumours. Tumours themselves within larger animals also tend to be comparatively smaller.  
The higher financial costs of carrying out canine tumour experiments compared with murine 
experiments is apparent [162]; however, dose-finding studies in mice may underestimate the 
dose necessary to achieve tumour colonisation in humans, due to incompatible physiologies. 
This may lead to more dissatisfactory patient responses in the clinical setting, ultimately 
leading to greater losses of time and money overall. Indeed, a canine study which compared 
intravenous and intratumoural administration with C. novyi-NT reported a significant anti-
















animal achieving a complete response when administration was intravenous [50]. Had such a 
study been conducted in mice, it is possible that intravenous administration may have been 
sufficient for tumour colonisation, giving perhaps a more distorted reflection of what might 
occur in human subjects. A further study in dogs injected intravenously with C. novyi-NT 
spores reported a high frequency of noxious events resulting from treatment [164].  
Gene therapy medicinal products are increasingly navigating their way into clinical trials, 
overseen by regulatory authorities which deliberate on whether the product makes it from one 
stage to the next. Regulatory authorities set stringent criteria against which the safety and 
efficacy of medicinal products are judged. This applies, too, to gene therapies, for which the 
use of live carriers to transmit therapeutic material warrants special regulatory consideration. 
Therapies containing live bacteria, up until now, have had a relatively weak foothold in the 
clinical armamentarium. Bacillus Calmette-Guerin (BCG), a treatment for non-muscle 
invasive bladder cancer, is the only live bacterial therapy that is currently approved by the 
Food and Drug Administration [165], and apart from being attenuated, is not genetically-
engineered [166, 167]. Safety assurance is key with bacterial treatments. Microbiological 
testing is a fundamental part of sound safety assessment of cancer gene therapies, and 
contamination of bacterial therapies with fungi, or indeed other bacteria, is a pressing 
regulatory concern [168]. In fact, recent shortages of BCG have been attributed to possible 
fungal contamination [169]. This underlines the importance of quality control and quality 
assurance in the manufacture of therapies like BDEPT.  
Genetically-engineered bacteria intended for in vivo applications face an atypical kind of 
regulatory hurdle in terms of safety assurance. The transference of resistance genes from 
genetically-engineered bacterial therapies to host microbiota and pathogenic agents could 
result in the genesis of antibiotic-resistant disease, compromising patient safety. Thus, 
bacteria must be rid of antibiotic resistance genes before administration to clinical trial 
subjects can take place. Even innocuous probiotic bacteria, when formulated as feed 
additives, must be devoid of antibiotic resistance genes before they can be approved for use 
in Europe [170]. Microbes, even those which have been genetically weakened, are at risk of 
being shed from the initial host and spread from person-to-person [168]. Thus, antibiotic-
resistant disease could manifest at both the intra- and inter-individual level. Bacteria should 
ideally be disabled from replication in the final product, and in case of their release into the 
environment, where they could be easily acquired by other individuals, their growth should 
















inclusion of antibiotic selection markers in bacterial strains [171]. They thereafter reported 
the first example of a bacterium, C. sporogenes, with a chromosomally-encoded prodrug-
converting enzyme that does not require antibiotic resistance genes [99]. The strain was also 
rendered auxotrophic by inhibiting its ability to synthesise pyrimidines, meaning that it would 
not proliferate if it were released into the environment. In doing so, they have invented a 
strain that potentially has a far more attractive safety profile for patients, which could help 
further ease regulators’ worries about the propagation of antibiotic resistance.  
 
BDEPT Prospects 
The ingredients necessary for transportation of BDEPT into the clinic may already be 
available, but their correct management and coordination by the designer will prove 
instrumental in building a meaningful product. As the bacterial carrier is the defining feature 
of this type of DEPT, a bacteria-centric focus stands to illuminate the way forward in terms 
of tackling deficiencies in BDEPT designs.  
There is much to learn from the technical shortcomings of recent preclinical investigations of 
BDEPT that can be instructive for prospective design attempts. It has been reported that 
lesser prodrug activation using BDEPT, compared with VDEPT, could be accounted for by 
disparities between viral and bacterial carriers which lead them to concentrate in different 
types of tissue [80]. Viruses, such as those derived from the murine leukaemia virus, gather 
only in viable, proliferating cells [18], while bacteria colonise both viable and necrotic tissues 
to different degrees, depending on their ability to thrive in oxygenated and deoxygenated 
environments. It may be constructive to bear this in mind at the design stage. The ideal 
bacterial carrier will colonise diverse types of tumour tissue. Poor colonisation of viable cells 
will diminish prodrug activation, while poor colonisation of hypoxic, necrotic tissue may 
affect therapeutic potential to reduce tumour growth. It would be prudent to clarify the 
intratumoural growth patterns of the bacterial carrier prior to its inclusion in the BDEPT 
design.  
Other bacterial properties which merit further investigation include the bacterial cell 
envelope. The Gram-positive periplasm is smaller than that of Gram-negative bacteria [172], 
which may explain why only the Gram-negative periplasm has been exploited in BDEPT to 
improve enzymatic activity; however, an unfamiliarity with the Gram-positive periplasm in 
















obstructive outer membrane, an enzyme incorporated into the Gram-positive periplasm will 
be more accessible to a circulating prodrug. The Gram-negative bacterial periplasm, although 
more familiar to the designer, is sheathed in greater membranous complexity. It may 
therefore be productive for BDEPT designers to investigate the use of the Gram-positive 
periplasm as a means of improving BDEPT efficacy. 
Both Gram-positive and Gram-negative bacteria contain membrane-associated efflux pumps 
which can export drugs from the bacterium [173, 174]. Efflux pumps are conventionally 
studied in the context of multidrug bacterial resistance against antibiotics, so not much is 
known about them in relation to chemotherapies. Nonetheless, there is speculation that they 
may be responsible for ejecting chemotherapeutic drugs from bacteria [110]. While this may 
have a hand in contributing to bacterial resistance to chemotherapeutic toxicity, efflux pumps 
could be seen alternatively as passageways through which an API may make its way outside 
a cell. Future BDEPT designs might benefit from considering the potential for efflux pumps 
to act as escape hatches for drugs which would otherwise be trapped by their unfavourable 
pharmacokinetics. Research into the effects of bacterial efflux pumps on chemotherapeutic 
drugs would be welcomed in this regard.  
Stimulating productivity in R&D is contingent on researchers keeping abreast of emerging 
technologies that could help expedite their products into the clinic. Synthetic biology is a 
novel scientific discipline which offers a profound design tool, giving its practitioners the 
means to bioengineer molecular circuits, enabling the design of ‘intelligent’ cellular systems 
[175]. It is a valuable discipline from a BDEPT perspective, because it allows its designers to 
assemble ‘parts’ (e.g. promoters and secretion tags) into ‘devices’ (e.g. a plasmid or 
chromosome) within host systems called ‘chassis’ (i.e. the bacterial carrier), permitting fine-
tuning of enzyme expression and function (Figure 6). Enzymatic constants like KM and kcat 
are relatively easy to predict. However, these constants change inside the chassis, making it 
difficult to calculate the kinetics of the enzyme. Synthetic biology can be utilised to fine-tune 


















Figure 6. The application of synthetic biology to BDEPT. Synthetic biology rationalises BDEPT systems design by reducing its holistic 
structure to well-characterised, functional “parts” which, in concert with one another, are built into a modular “device” to carry out a 
predefined role.  The device, when embedded in a chassis, forms a “system” which is fit to complete a task in accordance with its design. Within 
BDEPT, bacteria act as chassis for devices in the form of plasmids and chromosomes. These devices are equipped with various parts, e.g. 
















Synthetic biology has been investigated for its applicability in perfecting bacterial homing to 
tumours. While bacteria are indeed tumour-selective, clinical experience thus far underlines 
the reality that human tolerance of administered bacterial loads places restrictions on BDEPT 
dosing regimens [25, 27]. In fact, there are instances where even commensal bacteria have 
had dosage limitations placed upon them in preclinical studies [32]. From synthetic biology 
principles, synthetic adhesins have been assembled based on the β-barrel domain of intimin - 
an adhesin derived from pathogenic E. coli strains - and the variable immunoglobulin domain 
of heavy chain-only antibodies [176]. When affixed to bacteria, these adhesins raise the 
tumour-targeting capacity of the chassis, and reduce the bacterial titre required for tumour 
colonisation. 
Gene therapies in general have had scattered clinical fortune, and even those which are 
therapeutically efficacious and safe in clinical trials have ultimately been unusable due to 
commercial incompatibilities [177]. This means that BDEPT can undergo translation from 
bench-to-bedside, and its developers are still liable to be short-changed by additional 
blockades. It is therefore wise for the BDEPT designer to subject their product to wide-
angled scrutiny so weaknesses in their product can be uncovered at an early stage. 
Aside from potential design flaws of BDEPT keeping it from the clinic, its momentum could 
be hampered by external forces. A major determinant of a medicine’s quality concerns the 
types of institutions which contribute to its R&D. R&D of academic origin is sometimes 
reprimanded for its custom of turning out products that are unsatisfactory by industrial 
standards [178]. An awareness of this deficiency is particularly important, given that 
biotechnology companies, which act as industrial centres of innovation for therapies like 
BDEPT [179], are reliant on universities for the generation of many of their products [180]. It 
may be apt for academic BDEPT designers to liaise with industry sooner rather than later to 
permit synchronisation. 
This review makes it clear that there is a complex line of questioning the BDEPT designer 
must pursue to create a workable product, yet this kind of therapy holds much promise to 
become a breakthrough mainstay of cancer treatment.  The novelty of BDEPT makes it an 
especially lucrative avenue of R&D to explore, and its advent comes at a time of concern and 
precariousness in the pharmaceutical industry. A decline in R&D efficiency is evident, and it 
is speculated that it is becoming harder for novel medicines to reach the clinic, partly because 
















healthcare standards set by existing treatments [181]. BDEPT is opportunely positioned to 
overstep these hurdles. There is a need in oncology for safe, targeted medicines, whereas for 
other indications such as hypertension and asthma, standards of care are already impressive 
and tough to improve on. This creates an entry point for novel oncological medicines, like 
BDEPT, which does not exist as obviously with medicines for other indications, for which 
the bar might be set much higher.  
An indulgence in a field of drug discovery that has not yet begun to flourish may feel to the 
drug designer to be an overly risky endeavour. However, it is pertinent to recall that risk and 
prosperity in R&D go hand-in-hand [182]. Designers of BDEPT are potentially on the verge 
of forging a new, ground-breaking form of cancer therapy. How adeptly they will engage 
with this prospect will depend on their familiarity with the realities of R&D, and on their 
mastery of BDEPT design principles. 
 
Conclusion 
BDEPT possesses singular characteristics which differentiate it from other forms of gene 
therapy and directed enzyme prodrug therapy. These assets have placed it in the company of 
other promising treatments which aspire to control and cure malignant disease while 
minimising off-target damage. However, there are still obstacles which must be traversed 
before BDEPT can occupy a de facto position in the clinician’s anticancer repertory.  
BDEPT has experienced relatively little exposure to clinical testing thus far, but, to the extent 
that it has, it is notable that human subjects respond to treatment in a way that is sometimes 
inconsistent with preclinical findings. This disparity raises the question of how R&D 
practices should be strategized and enhanced to bridge the gap between clinical and 
preclinical observations.  
Bacteria are undeniably adept at preferential accumulation in malignant tissues, yet clinical 
reports have pointed out that the targeting potential of these microbes may be restricted by 
dosage limitations that apply even to attenuated bacteria. This concern is reflected in the 
myriad studies which seek to reduce bacterial titres needed for tumour colonisation by, for 
example, the optimisation of enzyme kinetics. The co-option of synthetic biology to engineer 
















This review provides a comprehensive guide to which researchers can refer as they continue 
to translate BDEPT into a clinically-viable medicine. Such a framework should prove 
especially useful at a time when BDEPT is still being tested clinically, amid abundant 
technological advancements which ought to work in its favour.  
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Figure 1. Bacterial-directed enzyme prodrug therapy. The two-step procedure of BDEPT 
is illustrated, wherein bacteria expressing a prodrug-converting enzyme are administered 
intravenously to an oncology patient (step 1), followed by intravenous administration of a 
corresponding prodrug when the tumour is adequately colonised (step 2). The bacterial-
mediated conversion of 5-fluorocytosine (a prodrug) to 5-fluorouracil (an API) is illustrated 
in step 2.  
 
Figure 2. BDEPT Design Process Flow. An illustration of the order in which the de novo 
design of BDEPT should be approached. The process is divided into five distinct design 
principles. Curved arrows pointing from one design principle to another indicate a 
relationship in which an understanding of the design principle being pointed to is dependent 
on a familiarity with the design principle from which the arrow comes.   
 
Figure 3. Enzymatic alignment strategies in BDEPT. An illustration of the various 
enzymatic conformations that have been investigated in BDEPT. The activation of 
hydrophilic prodrugs has been enhanced by coupling BDEPT enzymes to the surface or 
directing them to the periplasm of Gram-negative bacteria (e.g. E. coli BL21 and VNP20009, 
respectively). 
 
Figure 4. Toxic metabolite production via BDEPT enzymes. Fludarabine is converted by 
PNP to 2-fluoroadenine (C5H5N5F), while CB1954 is converted by NTR to DNA cross-
linking agents, all of which are potentially deleterious to bacteria via inhibition of DNA, 
RNA, and protein synthesis. 
 
Figure 5. BDEPT enzymatic activity detection. Therapeutic enzymatic activity may be 
detected in situ, or ex vivo. Direct in vivo detection can be accomplished by activation of a 
light-emitting probe by bacterially-expressed enzymes at the site of the tumour, followed by 
MI to acquire an image of the probe. Indirect detection may be achieved by analysis of blood 
or urine samples for probes that have been activated by bacterial enzymes in the tumour and 

















Figure 6. The application of synthetic biology to BDEPT. Synthetic biology rationalises 
BDEPT systems design by reducing its holistic structure to well-characterised, functional 
“parts” which, in concert with one another, are built into a modular “device” to carry out a 
predefined role. The device, when embedded in a chassis, forms a “system” which is fit to 
complete a task in accordance with its design. Within BDEPT, bacteria act as chassis for 
devices in the form of plasmids and chromosomes. These devices are equipped with various 
parts, e.g. secretion tags, which aim to coordinate the expression of a prodrug-converting 
enzyme.  
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